Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
mr001
Cancer
Nanfang Hospital, Southern Medical University
P1
C
(36)
Mrna-4106
Cancer
ModernaTX, Inc.
P1
C
(36)
Mrna-4200
Cancer
ModernaTX, Inc.
P1
C
(36)
Navoximod
Cancer
Luke, Jason, MD
P1
C
(36)
NBL-015 (ANTI-CLAUDIN18.2 MAB)
Cancer
NovaRock Biotherapeutics, Ltd
P1
C
(36)
nk042
Cancer
Shanghai NK Cell Technology Co., LTD
P1
C
(36)
NLG 802
Cancer
Luke, Jason, MD
P1
C
(36)
Odc-Il2
Cancer
Trutino Biosciences Inc.
P1
C
(36)
P1801
Cancer
PharmaEssentia
P1
C
(36)
Pas-004 Capsules
Cancer
Pasithea Therapeutics Corp.
P1
C
(36)
Pas-004 Tablets
Cancer
Pasithea Therapeutics Corp.
P1
C
(36)
pf-07265028
Cancer
Pfizer
P1
C
(36)
Phst001
Cancer
Pheast Therapeutics
P1
C
(36)
pur001
Cancer
Purinomia Biotech, Inc.
P1
C
(36)
qls31903
Cancer
Qilu Pharmaceutical Co., Ltd.
P1
C
(36)
qtx3544
Cancer
Quanta Therapeutics
P1
C
(36)
Recombinant Human Hyaluronidase
Cancer
AstraZeneca
P1
C
(36)
Recombinant Human Il-21-Expressing Oncolytic Vaccinia Virus
Cancer
Hangzhou Converd Co., Ltd.
P1
C
(36)
Rilvegostomig
Cancer
AstraZeneca
P1
C
(36)
Rmc-4630
Cancer
Amgen
P1
C
(36)
Rmc-5127
Cancer
Revolution Medicines, Inc.
P1
C
(36)
Rmc-9805
Cancer
Revolution Medicines, Inc.
P1
C
(36)
ROPEGINTERFERON ALFA-2B
Cancer
PharmaEssentia
P1
C
(36)
Ruserontinib
Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1
C
(36)
sg1827
Cancer
Hangzhou Sumgen Biotech Co., Ltd.
P1
C
(36)
Showing 326 to 350 of 423 assets
Previous
Page 14 of 17
Next
